SeaStar Medical(US:ICU) Globenewswire·2025-06-11 12:25Core Insights - The U.S. Department of Defense (DoD) has awarded a $2 million grant to the Autonomous Reanimation and Evacuation (AREVA) Research Institute for a study on SeaStar Medical's Selective Cytopheretic Device (SCD) therapy aimed at reducing hyperinflammation in patients with severe burns, inhalation injuries, and sepsis [1][2] - The research study is set to begin in July 2025 and will last for three years, focusing on the application of SCD therapy in military and civilian trauma cases [2][4] - The SCD therapy is designed to neutralize overactive immune cells and mitigate cytokine storms, which can lead to severe inflammation and organ failure [5] Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on improving care for critically ill patients at risk of organ failure, with its first product, QUELIMMUNE, receiving FDA approval in 2024 [6] - The SCD therapy has received six Breakthrough Device Designations from the FDA and is currently undergoing pivotal trials for adult acute kidney injury patients requiring continuous renal replacement therapy (CRRT) [6] - The collaboration with AREVA is seen as a significant opportunity to advance military medicine and improve outcomes for patients suffering from trauma-related conditions [3][4] Research and Development - The grant will facilitate the purchase of SCD therapy for the research study, which aims to enhance organ recovery and potentially reduce the need for dialysis in patients with severe acute inflammatory conditions [2][3] - The Geneva Foundation will provide operational support for the research program, ensuring its success and accelerating innovation in military medicine [3][8] - The study will evaluate the effectiveness of SCD therapy in optimizing recovery for critically wounded service members and may have broader applications in treating various acute and chronic diseases [4][5]